Research graph
References from Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 Season. Local targets link to admitted publications; unresolved targets remain external evidence.
Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: a systematic analysis of the Global Burden of Disease 2019 Study.
10.1016/j.ijid.2023.08.008 · 2023 · External reference
Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023.
10.15585/mmwr.mm7229a4 · 2023 · External reference
Assessing the real-world effectiveness of immunizations for respiratory syncytial virus.
10.1001/jama.2024.5859 · 2024 · External reference
Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults.
10.1056/nejmoa2207566 · 2023 · External reference
RSV vaccine effectiveness against hospitalization among US adults 60 years and older.
10.1001/jama.2024.15775 · 2024 · External reference
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
10.1016/s0140-6736(24)01738-0 · 2024 · External reference
Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older.
10.1001/jamanetworkopen.2025.8322 · 2025 · External reference
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
10.1016/s1473-3099(24)00796-5 · 2025 · External reference
Making neighborhood-disadvantage metrics accessible—The Neighborhood Atlas.
10.1056/nejmp1802313 · 2018 · External reference
Marginal structural models and causal inference in epidemiology.
10.1097/00001648-200009000-00011 · 2000 · External reference
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
10.1097/00001648-200009000-00012 · 2000 · External reference
A new look at the statistical model identification.
10.1109/tac.1974.1100705 · 1974 · External reference
Use of respiratory syncytial virus vaccines in adults aged =60 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024.
10.15585/mmwr.mm7332e1 · 2024 · External reference
Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
10.1016/s1473-3099(14)71087-4 · 2015 · External reference
Real-world effectiveness of mRNA COVID-19 vaccines among US nursing home residents aged =65 years in the pre-Delta and high Delta periods.
10.1093/ofid/ofae051 · 2024 · External reference
Relative effectiveness and waning of a third dose of mRNA COVID-19 vaccine in Medicare beneficiaries aged 65 years and older during the BA.1/BA.2 Omicron period.
10.1093/infdis/jiae503 · 2025 · External reference
Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations.
10.1371/journal.pone.0244746 · 2021 · External reference
Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure.
10.1093/cid/ciab125 · 2021 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
RSV vaccine effectiveness against hospitalization among US adults 60 years and older.
10.1001/jama.2024.15775 · ExternalCitation · doi-reference
Assessing the real-world effectiveness of immunizations for respiratory syncytial virus.
10.1001/jama.2024.5859 · ExternalCitation · doi-reference
Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older.
10.1001/jamanetworkopen.2025.8322 · ExternalCitation · doi-reference
Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: a systematic analysis of the Global Burden of Disease 2019 Study.
10.1016/j.ijid.2023.08.008 · ExternalCitation · doi-reference
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
10.1016/s0140-6736(24)01738-0 · ExternalCitation · doi-reference
Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
10.1016/s1473-3099(14)71087-4 · ExternalCitation · doi-reference
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
10.1016/s1473-3099(24)00796-5 · ExternalCitation · doi-reference
Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults.
10.1056/nejmoa2207566 · ExternalCitation · doi-reference
Making neighborhood-disadvantage metrics accessible—The Neighborhood Atlas.
10.1056/nejmp1802313 · ExternalCitation · doi-reference
Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure.
10.1093/cid/ciab125 · ExternalCitation · doi-reference
Relative effectiveness and waning of a third dose of mRNA COVID-19 vaccine in Medicare beneficiaries aged 65 years and older during the BA.1/BA.2 Omicron period.
10.1093/infdis/jiae503 · ExternalCitation · doi-reference
Real-world effectiveness of mRNA COVID-19 vaccines among US nursing home residents aged =65 years in the pre-Delta and high Delta periods.
10.1093/ofid/ofae051 · ExternalCitation · doi-reference
Marginal structural models and causal inference in epidemiology.
10.1097/00001648-200009000-00011 · ExternalCitation · doi-reference
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
10.1097/00001648-200009000-00012 · ExternalCitation · doi-reference
A new look at the statistical model identification.
10.1109/tac.1974.1100705 · ExternalCitation · doi-reference
Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations.
10.1371/journal.pone.0244746 · ExternalCitation · doi-reference
Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023.
10.15585/mmwr.mm7229a4 · ExternalCitation · doi-reference
Use of respiratory syncytial virus vaccines in adults aged =60 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024.
10.15585/mmwr.mm7332e1 · ExternalCitation · doi-reference
